GB2467494A - Materials and methods for medical imaging - Google Patents

Materials and methods for medical imaging Download PDF

Info

Publication number
GB2467494A
GB2467494A GB1009260A GB201009260A GB2467494A GB 2467494 A GB2467494 A GB 2467494A GB 1009260 A GB1009260 A GB 1009260A GB 201009260 A GB201009260 A GB 201009260A GB 2467494 A GB2467494 A GB 2467494A
Authority
GB
United Kingdom
Prior art keywords
conjugates
positron
materials
methods
labelling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB1009260A
Other versions
GB2467494B (en
GB201009260D0 (en
Inventor
Timothy Smith
Laurent Alain Claude Trembleau
Abbie Christina Mclaughlin
Michael Simpson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Aberdeen
Original Assignee
University of Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Aberdeen filed Critical University of Aberdeen
Publication of GB201009260D0 publication Critical patent/GB201009260D0/en
Publication of GB2467494A publication Critical patent/GB2467494A/en
Application granted granted Critical
Publication of GB2467494B publication Critical patent/GB2467494B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides

Abstract

The invention provides labelled platform conjugates, comprising (i) a labelling platformn (such as a dendrimer or nanoparticle) and (ii) a target binding moiety, wherein the labelling platform has at least one positron emitter attached thereto. The conjugates can be used to flexibly label antibodies or the like, with the positron emitted being added as a simple final step to a positron emitter attachment site, which is a particular advantage when using short halt-life isotopes such as18F. The invention further provides processes and materials for use in preparing the conjugates, and methods of imaging employing them e.g. in Positron Emission Tomography (PET).
GB1009260.9A 2007-11-02 2008-10-29 Materials and methods for medical imaging Expired - Fee Related GB2467494B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0721619A GB0721619D0 (en) 2007-11-02 2007-11-02 Materials and methods for medical imaging
PCT/GB2008/003678 WO2009056837A2 (en) 2007-11-02 2008-10-29 Materials and methods for medical imaging

Publications (3)

Publication Number Publication Date
GB201009260D0 GB201009260D0 (en) 2010-07-21
GB2467494A true GB2467494A (en) 2010-08-04
GB2467494B GB2467494B (en) 2012-05-23

Family

ID=38834797

Family Applications (2)

Application Number Title Priority Date Filing Date
GB0721619A Ceased GB0721619D0 (en) 2007-11-02 2007-11-02 Materials and methods for medical imaging
GB1009260.9A Expired - Fee Related GB2467494B (en) 2007-11-02 2008-10-29 Materials and methods for medical imaging

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB0721619A Ceased GB0721619D0 (en) 2007-11-02 2007-11-02 Materials and methods for medical imaging

Country Status (2)

Country Link
GB (2) GB0721619D0 (en)
WO (1) WO2009056837A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201110239D0 (en) 2011-06-17 2011-08-03 College The Labelling method

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2383534A (en) * 2001-12-28 2003-07-02 Psimei Pharmaceuticals Plc Delivery of neutron capture elements for neutron capture therapy
US20040258614A1 (en) * 2003-06-20 2004-12-23 University Of Maryland, Baltimore Microparticles for microarterial imaging and radiotherapy
WO2006044716A2 (en) * 2004-10-15 2006-04-27 Washington University In St.Louis CELL PERMEABLE NANOCONJUGATES OF SHELL-CROSSLINKED KNEDEL (SCK) AND PEPTIDE NUCLEIC ACIDS ('PNAs') WITH UNIQUELY EXPRESSED OR OVER-EXPRESSED mRNA TARGETING SEQUENCES FOR EARLY DIAGNOSIS AND THERAPY OF CANCER
WO2006064453A2 (en) * 2004-12-17 2006-06-22 Koninklijke Philips Electronics N.V. Targeting agents for molecular imaging
WO2007064175A1 (en) * 2005-12-02 2007-06-07 Industry-Academic Cooperation Foundation, Yonsei University Magnetic resonance imaging contrast agents containing water-soluble nanoparticles of manganese oxide or manganese metal oxide
WO2008121153A2 (en) * 2006-08-17 2008-10-09 University Of Utah Research Foundation Dendrimers and methods of making and using thereof
EP2000150A2 (en) * 2006-03-24 2008-12-10 Toto Ltd. Titanium oxide complex particle, dispersion solution of the particle, and process for production of the particle
WO2009045579A2 (en) * 2007-06-14 2009-04-09 The Regents Of The University Of California Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2383534A (en) * 2001-12-28 2003-07-02 Psimei Pharmaceuticals Plc Delivery of neutron capture elements for neutron capture therapy
US20040258614A1 (en) * 2003-06-20 2004-12-23 University Of Maryland, Baltimore Microparticles for microarterial imaging and radiotherapy
WO2006044716A2 (en) * 2004-10-15 2006-04-27 Washington University In St.Louis CELL PERMEABLE NANOCONJUGATES OF SHELL-CROSSLINKED KNEDEL (SCK) AND PEPTIDE NUCLEIC ACIDS ('PNAs') WITH UNIQUELY EXPRESSED OR OVER-EXPRESSED mRNA TARGETING SEQUENCES FOR EARLY DIAGNOSIS AND THERAPY OF CANCER
WO2006064453A2 (en) * 2004-12-17 2006-06-22 Koninklijke Philips Electronics N.V. Targeting agents for molecular imaging
WO2007064175A1 (en) * 2005-12-02 2007-06-07 Industry-Academic Cooperation Foundation, Yonsei University Magnetic resonance imaging contrast agents containing water-soluble nanoparticles of manganese oxide or manganese metal oxide
EP2000150A2 (en) * 2006-03-24 2008-12-10 Toto Ltd. Titanium oxide complex particle, dispersion solution of the particle, and process for production of the particle
WO2008121153A2 (en) * 2006-08-17 2008-10-09 University Of Utah Research Foundation Dendrimers and methods of making and using thereof
WO2009045579A2 (en) * 2007-06-14 2009-04-09 The Regents Of The University Of California Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"18F-labeling of peptides by means of an organosilicon-based fluoride acceptor", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol 45, no 36, 2006, 6047-6050, Schirrmacher et al. *
"An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface", BIOMACROMOLECULES, vol 6, no 5, 2005, 2542-2545, Sun Xiankai, et al. *
"Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis", Proceedings of the National Academy of Sciences of the United States (PNAS), vol 106, no 3, 685-690, Almutairi et al. *
"Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: Synthesis, radiolabeling, and biologic evaluation", JOURNAL OF NUCLEAR MEDICINE, vol 46, no 7, 2005, 1210-1218, Rossin R, et al. *
"Fluorine -18-Labeled Monoclonal antibody Fragments: A Potential Approach for Combining Radioimmunoscintigraphy and Positron emission Tomography", JOURNAL OF NUCLEAR MEDICINE, vol 33, no 8, 1992, 1535-1541, VAIDYANATHAN G, ET AL. *
"In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice", NATURE NANOTECHNOLOGY, vol 2, 2006, Liu et al. *
"Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers", IMMUNOTECHNOLOGY, vol 2, no 1, 21-36, Wu et al. *

Also Published As

Publication number Publication date
GB0721619D0 (en) 2007-12-12
WO2009056837A2 (en) 2009-05-07
WO2009056837A3 (en) 2010-01-14
GB2467494B (en) 2012-05-23
GB201009260D0 (en) 2010-07-21

Similar Documents

Publication Publication Date Title
AR066395A1 (en) REOVIRUS THAT HAVE MODIFIED SEQUENCES
EP1946787A3 (en) Syringe and syringe label
BRPI0519317A2 (en) Method for labeling a vector, compound, radiopharmaceutical composition, use of a compound, and methods for generating an image of a human or animal body and for monitoring the effect of treating a human or animal body with a drug to combat an associated condition. with cancer
PT103200B (en) POSITRON EMISSION TOMOGRAPHY SYSTEM (PET)
WO2015073746A3 (en) 18f labeling of proteins using sortases
WO2007148089A3 (en) Radiolabelling methods
NZ606466A (en) Peptide radiotracer compositions
CL2008001682A1 (en) Methods for plant improvement through the use of direct nucleic acid sequence information.
WO2008033557A3 (en) Click chemistry-derived cyclic peptidomimetics as integrin markers
WO2009052970A3 (en) Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors
MX2013007699A (en) Eluent solution.
MX2011010295A (en) Radiolabelling reagents and methods.
GB201013767D0 (en) Identification of ligands and their use
UY30595A1 (en) METHODS OF MARKING WITH RADIOACTIVE FLUOR
WO2006093966A3 (en) Sem cathodoluminescent imaging using up-converting nanophosphors
EP2232430A4 (en) Medical product management methods
NO20054615L (en) Mikrobolgemetode
EP4218829A3 (en) Activity-based probe compounds, compositions, and methods of use
WO2009134405A3 (en) Substrate based pet imaging agents
WO2009018175A3 (en) Cyclic azapeptides as integrin markers
UY30596A1 (en) MARKING WITH RADIOACTIVE FLUOR
GB2467494A (en) Materials and methods for medical imaging
WO2009025914A3 (en) Radiolabelled fluorobenzamide analogues, their synthesis and use in diagnostic imaging
AR071966A1 (en) CANULA IN SPECIAL FOR REGIONAL ANESTHESIA
WO2012149552A3 (en) Dual-isotope positron emitting tomography for disease evaluation

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20151029